<DOC>
	<DOCNO>NCT01531712</DOCNO>
	<brief_summary>Phase II study neoadjuvant treatment Gemcitabine , Tarceva Oxaliplatin follow chemotherapy Tarceva Gemcitabine patient pancreatic adenocarcinoma borderline resectability . The primary objective determine resectability rate patient pancreas adenocarcinoma borderline resectability determine radiologically , treat Gemcitabine , Tarceva Oxaliplatin follow radiotherapy Gemcitabine Tarceva .</brief_summary>
	<brief_title>Study Neoadjuvant Treatment Patients With Pancreatic Cancer That Potentially Resectable</brief_title>
	<detailed_description>Patients borderline resectable pancreatic adenocarcinoma likely develop perioperative complication due complexity surgery . In patient also increase risk systemic relapse due advance stage tumor well high possibility positive margin . Therefore , treatment patient need decide base multidisciplinary strategy . Besides use systemic neoadjuvant chemotherapy induction therapy , follow sequential chemoradiotherapy attractive therapeutic modality . The neoadjuvant treatment offer potential advantage reduce tumor stage , increase resectability decrease postoperative complication . The administration chemotherapy radiotherapy surgery represent strategy early treatment micrometastatic disease , present patient , identify patient rapid progression disease . For reason , investigator consider 's great interest design new study combine systemic neoadjuvant chemotherapy follow chemoradiotherapy neoadjuvant intention patient pancreas cancer locally advance .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Before begin specific protocol procedure must obtain document write consent form . Patients must sufficient capacity understand sign consent form . Exocrine pancreatic potentially resectable carcinoma , histologically confirm . Aged 1875 year . OMS functional state ( FE ) 02 Karnofsky functional state 70 % . Radiologically measurable disease , define borderline resectability disease . Appropriate biological parameter : neutrophil &gt; 1.500/mL ; platelet &gt; 100.000/mL ; hemoglobin &gt; 10 g/dl.Serum creatinine &lt; 1,5 x upper limit normal ( LSN ) ; alkaline phosphatase &lt; 3 x LSN bilirubin &lt; 1,5 x LSN ; AST ALT 2,5 x LSN . Controlled biliary obstruction patient inclusion study . Absence peripheral neuropathy grade 2 . Life expectancy least 3 month . Previous administration chemotherapy , radiotherapy investigational agent pancreatic cancer treatment . Administration experimental treatment study previous 6 month . Pregnancy , inappropriate unsafe use contraceptive method woman breastfeed . Clinically significant heart disease ( example : congestive heart failure , symptomatic coronary artery disease cardiac arrhythmias properly control medication myocardial infarction last 12 month ) . Presence significant ophthalmologic anomaly , include : severe dry eye syndrome , Sjogren syndrome , dry keratoconjunctivitis , severe exposure keratopathy , condition might increase risk epithelium complication . Patients lack physical integrity upper gastrointestinal tract bad absorption syndrome unable ingest tablet . Other previous bad concurrent disease , exception nonmelanoma skin cancer . Medical psychiatric pathology severe uncontrolled . Distant metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>neoadjuvant treatment</keyword>
	<keyword>borderline resectability</keyword>
</DOC>